Standard Antibiotics treatment duration — Competitive Intelligence Brief

Standard Antibiotics treatment duration (Standard Antibiotics treatment duration) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic. Area: Infectious diseases.

phase 3 Beta-lactam antibiotic Penicillin-binding proteins Infectious diseases Small molecule

Target snapshot

Standard Antibiotics treatment duration (Standard Antibiotics treatment duration) — University of Oxford. Standard antibiotics target and kill bacteria by inhibiting their cell wall synthesis or interfering with their protein synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard Antibiotics treatment duration TARGET	Standard Antibiotics treatment duration	University of Oxford	phase 3	Beta-lactam antibiotic	Penicillin-binding proteins
CEPHALEXIN	CEPHALEXIN		marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)	1971-01-01
Colistin/Polymyxin B + Meropenem	Colistin/Polymyxin B + Meropenem	National University of Singapore	marketed	Antibiotic combination (polymyxin + carbapenem)	Bacterial cell membrane (polymyxins) and bacterial cell wall/penicillin-binding proteins (meropenem)
Cefepime, Meropenem, or Piperacillin/Tazobactam	Cefepime, Meropenem, or Piperacillin/Tazobactam	University of Florida	marketed	Beta-lactam antibiotic (cephalosporin, carbapenem, or aminopenicillin with beta-lactamase inhibitor)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
I.V ampicillin 2 gram x4/d for 2 days	I.V ampicillin 2 gram x4/d for 2 days	Western Galilee Hospital-Nahariya	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs); bacterial peptidoglycan
omeprazole plus amoxicillin	omeprazole plus amoxicillin	National Taiwan University Hospital	marketed	Proton pump inhibitor + beta-lactam antibiotic combination	Proton pump (H+/K+-ATPase) and bacterial cell wall (penicillin-binding proteins)
Imipenem/Cilastatin/Relebactam	Imipenem/Cilastatin/Relebactam	Evopoint Biosciences Inc.	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; serine beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic class)

1. Pfizer · 2 drugs in this class
2. Bayer · 1 drug in this class
3. Belén Retamal-Valdes · 1 drug in this class
4. Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
5. Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
6. Incheon St.Mary's Hospital · 1 drug in this class
7. International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
8. KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
9. National Taiwan University Hospital · 1 drug in this class
10. Pfizer Inc. · 1 drug in this class